RAS Mutation Clinical Trials

9 recruiting

RAS Mutation Trials at a Glance

14 actively recruiting trials for ras mutation are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 8 trials, with the heaviest enrollment activity in Washington D.C., Fairfax, and Irving. Lead sponsors running ras mutation studies include Fudan University, Jiangsu HengRui Medicine Co., Ltd., and Beijing Hospital.

Browse ras mutation trials by phase

Treatments under study

About RAS Mutation Clinical Trials

Looking for clinical trials for RAS Mutation? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new RAS Mutation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about RAS Mutation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1Phase 2

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Lung CancerNSCLCThoracic Cancer+5 more
Tango Therapeutics, Inc.183 enrolled18 locationsNCT06922591
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Phase 1

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Pancreatic CancerLung CancerColon Cancer+3 more
RasCal Therapeutics, Inc.134 enrolled3 locationsNCT04678648
Recruiting
Phase 1

A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.120 enrolled1 locationNCT07189949
Recruiting
Phase 1

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Solid TumorKRAS Mutation-Related Tumors
Georgetown University24 enrolled1 locationNCT05661201
Recruiting
Phase 1

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

RAS MutationSolid Tumors (Phase 1)
Adlai Nortye Biopharma Co., Ltd.91 enrolled2 locationsNCT07252479
Recruiting

RASopathy Biorepository

RAS MutationNeurofibromatosis 1Noonan Syndrome+11 more
Children's Hospital Medical Center, Cincinnati1,000 enrolled1 locationNCT04395495
Recruiting
Phase 1

PAS-004 in Patients With Advanced Solid Tumors

Advanced Solid TumorsRAS MutationNF1 Mutation+1 more
Pasithea Therapeutics Corp.48 enrolled7 locationsNCT06299839
Recruiting
Phase 1

A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.120 enrolled1 locationNCT07142980
Recruiting
Phase 2

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University40 enrolled1 locationNCT06970353
Recruiting

Hematological Anomalies in Children With Rasopathy

RAS Mutation
Assistance Publique - Hôpitaux de Paris300 enrolled14 locationsNCT04286360
Recruiting
Phase 2

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Metastatic Colorectal CancerRAS MutationMSS
Beijing Hospital60 enrolled1 locationNCT06321081
Recruiting
Phase 2

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal CancerRAS MutationCadonilimab+1 more
Fudan University53 enrolled1 locationNCT06218810
Recruiting
Phase 2

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Lung CancerMelanomaPancreas Cancer+4 more
N.N. Petrov National Medical Research Center of Oncology20 enrolled1 locationNCT06229340